{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T10:37:29Z","timestamp":1789295849866,"version":"build-2803163510"},"reference-count":201,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003819","name":"Natural Science Foundation of Hubei Province","doi-asserted-by":"publisher","award":["2022CFB171"],"award-info":[{"award-number":["2022CFB171"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003787","name":"Hebei Provincial Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003787","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFA1303502"],"award-info":[{"award-number":["2022YFA1303502"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81903863"],"award-info":[{"award-number":["81903863"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.bcp.2026.117888","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:17:14Z","timestamp":1773361034000},"page":"117888","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Therapeutic targeting of tricarboxylic acid cycle and oxidative phosphorylation: a critical analysis of metabolic interventions in cancer treatment"],"prefix":"10.1016","volume":"249","author":[{"given":"Yawei","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhao","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanting","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4488-8008","authenticated-orcid":false,"given":"Mengzhu","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2026.117888_b0005","doi-asserted-by":"crossref","unstructured":"F. Bray, M. Laversanne, H. Sung, J. Ferlay, R.L. Siegel, I. Soerjomataram, A. Jemal, Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians 2024, 74(3):229-263. Doi: 10.3322\/caac.21834.","DOI":"10.3322\/caac.21834"},{"issue":"9","key":"10.1016\/j.bcp.2026.117888_b0010","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21093363","article-title":"Mitochondria targeting as an effective strategy for cancer therapy","volume":"21","author":"Ghosh","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.bcp.2026.117888_b0015","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8122161","article-title":"Rescue of TCA cycle dysfunction for cancer therapy","volume":"8","author":"Marquez","year":"2019","journal-title":"J. Clin. Med."},{"issue":"3","key":"10.1016\/j.bcp.2026.117888_b0020","doi-asserted-by":"crossref","first-page":"897","DOI":"10.7150\/ijbs.81609","article-title":"An overview: the diversified role of mitochondria in cancer metabolism","volume":"19","author":"Liu","year":"2023","journal-title":"Int. J. Biol. Sci."},{"issue":"3191","key":"10.1016\/j.bcp.2026.117888_b0025","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1126\/science.123.3191.309","article-title":"On the origin of cancer cells","volume":"123","author":"Warburg","year":"1956","journal-title":"Science (New York, N.Y.)"},{"issue":"2","key":"10.1016\/j.bcp.2026.117888_b0030","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s13238-017-0451-1","article-title":"The emerging role and targetability of the TCA cycle in cancer metabolism","volume":"9","author":"Anderson","year":"2018","journal-title":"Protein Cell"},{"issue":"11","key":"10.1016\/j.bcp.2026.117888_b0035","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1158\/1078-0432.CCR-17-3070","article-title":"Oxidative phosphorylation as an emerging target in cancer therapy","volume":"24","author":"Ashton","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"Pt 2","key":"10.1016\/j.bcp.2026.117888_b0040","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.semcancer.2022.02.002","article-title":"Targeting OXPHOS and the electron transport chain in cancer; molecular and therapeutic implications","volume":"86","author":"Greene","year":"2022","journal-title":"Semin. Cancer Biol."},{"issue":"18","key":"10.1016\/j.bcp.2026.117888_b0045","doi-asserted-by":"crossref","first-page":"9964","DOI":"10.1073\/pnas.1913633117","article-title":"Triptolide suppresses IDH1-mutated malignancy via Nrf2-driven glutathione metabolism","volume":"117","author":"Yu","year":"2020","journal-title":"PNAS"},{"issue":"9","key":"10.1016\/j.bcp.2026.117888_b0050","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1200\/JCO.2013.51.0214","article-title":"Vascular endothelial growth factor receptor-targeted therapy in succinate dehydrogenase C kidney cancer","volume":"34","author":"Shuch","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.bcp.2026.117888_b0055","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1038\/s41388-020-01639-8","article-title":"The functional roles of TCA cycle metabolites in cancer","volume":"40","author":"Eniafe","year":"2021","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.bcp.2026.117888_b0060","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.bbabio.2016.12.003","article-title":"Metabolic synthetic lethality in cancer therapy","volume":"1858","author":"Zecchini","year":"2017","journal-title":"Biochim. Biophys. Acta"},{"issue":"8","key":"10.1016\/j.bcp.2026.117888_b0065","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nrd.2018.123","article-title":"Metabolic synthetic lethality","volume":"17","author":"Villanueva","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"issue":"642","key":"10.1016\/j.bcp.2026.117888_b0070","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1086\/279847","article-title":"The origin of variations in sexual and sex-limited characters","volume":"56","author":"Bridges","year":"1922","journal-title":"Am. Nat."},{"issue":"3","key":"10.1016\/j.bcp.2026.117888_b0075","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1093\/genetics\/31.3.269","article-title":"Genetics of natural populations; recombination and variability in populations of Drosophila pseudoobscura","volume":"31","author":"Dobzhansky","year":"1946","journal-title":"Genetics"},{"issue":"1","key":"10.1016\/j.bcp.2026.117888_b0080","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/genetics\/59.1.37","article-title":"Synthetic lethality and semi-lethality among functionally related mutants of Drosophila melanfgaster","volume":"59","author":"Lucchesi","year":"1968","journal-title":"Genetics"},{"issue":"23","key":"10.1016\/j.bcp.2026.117888_b0085","doi-asserted-by":"crossref","first-page":"14151","DOI":"10.1021\/acs.jmedchem.0c00766","article-title":"Synthetic lethality through the lens of medicinal chemistry","volume":"63","author":"Myers","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.117888_b0090","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.biochi.2017.02.008","article-title":"Genetic alterations in Krebs cycle and its impact on cancer pathogenesis","volume":"135","author":"Sajnani","year":"2017","journal-title":"Biochimie"},{"issue":"7300","key":"10.1016\/j.bcp.2026.117888_b0095","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/nature09132","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"465","author":"Dang","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2026.117888_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154297","article-title":"Targeting pheochromocytoma\/paraganglioma with polyamine inhibitors","volume":"110","author":"Rai","year":"2020","journal-title":"Metab. Clin. Exp."},{"key":"10.1016\/j.bcp.2026.117888_b0105","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1146\/annurev.bb.15.060186.000525","article-title":"Citrate synthase: structure, control, and mechanism","volume":"15","author":"Wiegand","year":"1986","journal-title":"Annu. Rev. Biophys. Biophys. Chem."},{"key":"10.1016\/j.bcp.2026.117888_b0110","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/srep00785","article-title":"Loss of the respiratory enzyme citrate synthase directly links the Warburg effect to tumor malignancy","volume":"2","author":"Lin","year":"2012","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2026.117888_b0115","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/2049-3002-2-10","article-title":"Defects in mitochondrial metabolism and cancer","volume":"2","author":"Gaude","year":"2014","journal-title":"Cancer Metab."},{"issue":"3","key":"10.1016\/j.bcp.2026.117888_b0120","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ccr.2012.02.014","article-title":"Metabolic reprogramming: a cancer hallmark even warburg did not anticipate","volume":"21","author":"Ward","year":"2012","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.bcp.2026.117888_b0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115708","article-title":"Citrate synthase expression affects tumor phenotype and drug resistance in human ovarian carcinoma","volume":"9","author":"Chen","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.bcp.2026.117888_b0130","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/01.mpa.0000153326.69816.7d","article-title":"Enhanced citrate synthase activity in human pancreatic cancer","volume":"30","author":"Schlichtholz","year":"2005","journal-title":"Pancreas"},{"issue":"35","key":"10.1016\/j.bcp.2026.117888_b0135","doi-asserted-by":"crossref","first-page":"37758","DOI":"10.18632\/oncotarget.5386","article-title":"Application of mitochondrial pyruvate carrier blocker UK5099 creates metabolic reprogram and greater stem-like properties in LnCap prostate cancer cells in vitro","volume":"6","author":"Zhong","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2026.117888_b0140","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1476-4598-5-14","article-title":"Mitochondrial aconitase and citrate metabolism in malignant and nonmalignant human prostate tissues","volume":"5","author":"Singh","year":"2006","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2026.117888_b0145","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41467-019-13668-3","article-title":"Mitochondrial TCA cycle metabolites control physiology and disease","volume":"11","author":"Mart\u00ednez-Reyes","year":"2020","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.bcp.2026.117888_b0150","first-page":"1468","article-title":"Mammalian iron metabolism and its control by iron regulatory proteins","volume":"1823","author":"Anderson","year":"2012","journal-title":"BBA"},{"issue":"1","key":"10.1016\/j.bcp.2026.117888_b0155","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1038\/s41467-019-13237-8","article-title":"Glycogen branching enzyme controls cellular iron homeostasis via iron regulatory protein 1 and mitoNEET","volume":"10","author":"Huynh","year":"2019","journal-title":"Nat. Commun."},{"issue":"30","key":"10.1016\/j.bcp.2026.117888_b0160","doi-asserted-by":"crossref","first-page":"22369","DOI":"10.1016\/S0021-9258(18)41538-4","article-title":"The inactivation of Fe-S cluster containing hydro-lyases by superoxide","volume":"268","author":"Flint","year":"1993","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2026.117888_b0165","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/13510002.2020.1787662","article-title":"Generation of reactive oxygen species by hydroxypyridone compound\/iron complexes","volume":"25","author":"Murakami","year":"2020","journal-title":"Redox Report: Communications in Free Radical Research"},{"issue":"2","key":"10.1016\/j.bcp.2026.117888_b0170","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1007\/s12032-013-0552-5","article-title":"Decreased expression of the mitochondrial metabolic enzyme aconitase (ACO2) is associated with poor prognosis in gastric cancer","volume":"30","author":"Wang","year":"2013","journal-title":"Med. Oncol. (Northwood, London, England)"},{"issue":"2","key":"10.1016\/j.bcp.2026.117888_b0175","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/s41416-019-0641-0","article-title":"Aconitase 2 inhibits the proliferation of MCF-7 cells promoting mitochondrial oxidative metabolism and ROS\/FoxO1-mediated autophagic response","volume":"122","author":"Ciccarone","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.bcp.2026.117888_b0180","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1007\/s13311-022-01238-3","article-title":"Targeting IDH-mutant glioma","volume":"19","author":"Miller","year":"2022","journal-title":"Neurotherapeutics: J. Am. Soc. Experim. NeuroTherapeutics"},{"issue":"32","key":"10.1016\/j.bcp.2026.117888_b0185","doi-asserted-by":"crossref","first-page":"33946","DOI":"10.1074\/jbc.M404298200","article-title":"Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity","volume":"279","author":"Xu","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.bcp.2026.117888_b0190","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1182\/blood-2017-04-779447","article-title":"Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response","volume":"130","author":"Amatangelo","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bcp.2026.117888_b0195","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/embor.2011.43","article-title":"The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases","volume":"12","author":"Chowdhury","year":"2011","journal-title":"EMBO Rep."},{"issue":"7390","key":"10.1016\/j.bcp.2026.117888_b0200","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/nature10860","article-title":"IDH mutation impairs histone demethylation and results in a block to cell differentiation","volume":"483","author":"Lu","year":"2012","journal-title":"Nature"},{"issue":"7390","key":"10.1016\/j.bcp.2026.117888_b0205","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nature10866","article-title":"IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype","volume":"483","author":"Turcan","year":"2012","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.bcp.2026.117888_b0210","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkaf512","article-title":"R-2-hydroxyglutarate-mediated inhibition of KDM4A compromises telomere integrity","volume":"53","author":"Couteau","year":"2025","journal-title":"Nucleic Acids Res."},{"issue":"2","key":"10.1016\/j.bcp.2026.117888_b0215","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.molcel.2024.12.012","article-title":"Metabolism-driven chromatin dynamics: Molecular principles and technological advances","volume":"85","author":"Sahu","year":"2025","journal-title":"Mol. Cell"},{"issue":"4","key":"10.1016\/j.bcp.2026.117888_b0220","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00277-020-03938-2","article-title":"Updates on DNA methylation modifiers in acute myeloid leukemia","volume":"99","author":"Contieri","year":"2020","journal-title":"Ann. Hematol."},{"issue":"12","key":"10.1016\/j.bcp.2026.117888_b0225","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1080\/14737159.2018.1548935","article-title":"The clinical use of IDH1 and IDH2 mutations in gliomas","volume":"18","author":"Picca","year":"2018","journal-title":"Expert Rev. Mol. Diagn."},{"issue":"6","key":"10.1016\/j.bcp.2026.117888_b0230","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.jos.2021.07.024","article-title":"Prognostic impact of IDH mutations in chondrosarcoma","volume":"27","author":"Nakagawa","year":"2022","journal-title":"J. Orthopaedic Sci.: Off. J. Jpn. Orthopaedic Assoc."},{"issue":"9","key":"10.1016\/j.bcp.2026.117888_b0235","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1080\/13543784.2018.1512581","article-title":"Novel targeted treatment options for advanced cholangiocarcinoma","volume":"27","author":"Mahipal","year":"2018","journal-title":"Expert Opin. Invest. Drugs"},{"issue":"18","key":"10.1016\/j.bcp.2026.117888_b0240","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231810869","article-title":"IDH inhibitors and immunotherapy for biliary tract cancer: a marriage of convenience?","volume":"23","author":"Brandi","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"24","key":"10.1016\/j.bcp.2026.117888_b0245","doi-asserted-by":"crossref","first-page":"7118","DOI":"10.1158\/0008-5472.CAN-16-0298","article-title":"IDH2 mutations define a unique subtype of breast cancer with altered nuclear polarity","volume":"76","author":"Chiang","year":"2016","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.bcp.2026.117888_b0250","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJMoa0903840","article-title":"Recurring mutations found by sequencing an acute myeloid leukemia genome","volume":"361","author":"Mardis","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.117888_b0255","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1634\/theoncologist.2011-0386","article-title":"Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping","volume":"17","author":"Borger","year":"2012","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.bcp.2026.117888_b0260","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/path.2913","article-title":"IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours","volume":"224","author":"Amary","year":"2011","journal-title":"J. Pathol."},{"issue":"52","key":"10.1016\/j.bcp.2026.117888_b0265","doi-asserted-by":"crossref","first-page":"15084","DOI":"10.1073\/pnas.1617929114","article-title":"The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development","volume":"113","author":"Lemonnier","year":"2016","journal-title":"PNAS"},{"issue":"6","key":"10.1016\/j.bcp.2026.117888_b0270","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1111\/his.13707","article-title":"Isocitrate dehydrogenase 1 mutations in melanoma frequently co-occur with NRAS mutations","volume":"73","author":"Linos","year":"2018","journal-title":"Histopathology"},{"issue":"3","key":"10.1016\/j.bcp.2026.117888_b0275","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.celrep.2016.09.052","article-title":"Differential aspartate usage identifies a subset of cancer cells particularly dependent on OGDH","volume":"17","author":"Allen","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.bcp.2026.117888_b0280","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40170-017-0165-0","article-title":"The \u03b1-ketoglutarate dehydrogenase complex in cancer metabolic plasticity","volume":"5","author":"Vatrinet","year":"2017","journal-title":"Cancer Metab."},{"issue":"7","key":"10.1016\/j.bcp.2026.117888_b0285","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/s41419-018-0802-8","article-title":"\u03b1-ketoglutarate dehydrogenase inhibition counteracts breast cancer-associated lung metastasis","volume":"9","author":"Atlante","year":"2018","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.bcp.2026.117888_b0290","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/s41420-023-01475-1","article-title":"\u03b1-KG inhibits tumor growth of diffuse large B-cell lymphoma by inducing ROS and TP53-mediated ferroptosis","volume":"9","author":"Cai","year":"2023","journal-title":"Cell Death Discovery"},{"issue":"2","key":"10.1016\/j.bcp.2026.117888_b0295","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41419-023-05692-5","article-title":"Supplementation with \u03b1-ketoglutarate improved the efficacy of anti-PD1 melanoma treatment through epigenetic modulation of PD-L1","volume":"14","author":"Liu","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bcp.2026.117888_b0300","doi-asserted-by":"crossref","unstructured":"Q. Hu, J. Xu, L. Wang, Y. Yuan, R. Luo, M. Gan, K. Wang, T. Zhao, Y. Wang, T. Han, et al., SUCLG2 regulates mitochondrial dysfunction through succinylation in lung adenocarcinoma. Adv. Sci. (Weinheim, Baden-Wurttemberg, Germany) 2023, 10(35):e2303535. Doi: 10.1002\/advs.202303535.","DOI":"10.1002\/advs.202303535"},{"issue":"23","key":"10.1016\/j.bcp.2026.117888_b0305","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2217332120","article-title":"Succinyl-CoA ligase ADP-forming subunit beta promotes stress granule assembly to regulate redox and drive cancer metastasis","volume":"120","author":"Boese","year":"2023","journal-title":"PNAS"},{"issue":"11","key":"10.1016\/j.bcp.2026.117888_b0310","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/j.molcel.2021.04.002","article-title":"SUCLA2-coupled regulation of GLS succinylation and activity counteracts oxidative stress in tumor cells","volume":"81","author":"Tong","year":"2021","journal-title":"Mol. Cell"},{"issue":"7","key":"10.1016\/j.bcp.2026.117888_b0315","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.cell.2005.05.025","article-title":"Crystal structure of mitochondrial respiratory membrane protein complex II","volume":"121","author":"Sun","year":"2005","journal-title":"Cell"},{"issue":"14","key":"10.1016\/j.bcp.2026.117888_b0320","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1158\/0008-5472.CAN-15-2637","article-title":"S-nitrosylation of the mitochondrial chaperone TRAP1 sensitizes hepatocellular carcinoma cells to inhibitors of succinate dehydrogenase","volume":"76","author":"Rizza","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2026.117888_b0325","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.canlet.2020.02.009","article-title":"Melatonin alleviates progression of uterine endometrial cancer by suppressing estrogen\/ubiquitin C\/SDHB-mediated succinate accumulation","volume":"476","author":"Gu","year":"2020","journal-title":"Cancer Lett."},{"issue":"6636","key":"10.1016\/j.bcp.2026.117888_b0330","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1126\/science.abm3452","article-title":"Protein-metabolite interactomics of carbohydrate metabolism reveal regulation of lactate dehydrogenase","volume":"379","author":"Hicks","year":"2023","journal-title":"Science (New York, N.Y.)"},{"issue":"3","key":"10.1016\/j.bcp.2026.117888_b0335","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.taap.2013.07.009","article-title":"Quantitative proteomic analysis of the inhibitory effects of CIL-102 on viability and invasiveness in human glioma cells","volume":"272","author":"Teng","year":"2013","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"7363","key":"10.1016\/j.bcp.2026.117888_b0340","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nature10363","article-title":"Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase","volume":"477","author":"Frezza","year":"2011","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.bcp.2026.117888_b0345","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1038\/s41416-023-02412-w","article-title":"Fumarate hydratase (FH) and cancer: a paradigm of oncometabolism","volume":"129","author":"Valcarcel-Jimenez","year":"2023","journal-title":"Br. J. Cancer"},{"issue":"8","key":"10.1016\/j.bcp.2026.117888_b0350","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0072179","article-title":"Metabolic reprogramming for producing energy and reducing power in fumarate hydratase null cells from hereditary leiomyomatosis renal cell carcinoma","volume":"8","author":"Yang","year":"2013","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.bcp.2026.117888_b0355","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1101\/gad.191056.112","article-title":"Inhibition of \u03b1-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors","volume":"26","author":"Xiao","year":"2012","journal-title":"Genes Dev."},{"key":"10.1016\/j.bcp.2026.117888_b0360","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/8554844","article-title":"Pan-cancer analysis reveals FH as a potential prognostic and immunological biomarker in lung adenocarcinoma","volume":"2021","author":"Zhang","year":"2021","journal-title":"Dis. Markers"},{"issue":"2","key":"10.1016\/j.bcp.2026.117888_b0365","first-page":"530","article-title":"Methanol dehydrogenase, a key enzyme of one-carbon metabolism: a review","volume":"37","author":"Fan","year":"2021","journal-title":"Sheng Wu Gong Cheng Xue Bao = Chinese Journal of Biotechnology"},{"issue":"11","key":"10.1016\/j.bcp.2026.117888_b0370","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1016\/j.cmet.2024.09.014","article-title":"Metabolic regulation of the glioblastoma stem cell epitranscriptome by malate dehydrogenase 2","volume":"36","author":"Lv","year":"2024","journal-title":"Cell Metab."},{"issue":"23","key":"10.1016\/j.bcp.2026.117888_b0375","doi-asserted-by":"crossref","first-page":"14276","DOI":"10.1021\/acs.jmedchem.0c01013","article-title":"Why all the fuss about oxidative phosphorylation (OXPHOS)?","volume":"63","author":"Xu","year":"2020","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.bcp.2026.117888_b0380","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1001129","article-title":"Tracing the trail of protons through complex I of the mitochondrial respiratory chain","volume":"9","author":"Mourier","year":"2011","journal-title":"PLoS Biol."},{"issue":"8031","key":"10.1016\/j.bcp.2026.117888_b0385","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/s41586-024-07812-3","article-title":"Mitochondrial complex I promotes kidney cancer metastasis","volume":"633","author":"Bezwada","year":"2024","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.bcp.2026.117888_b0390","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/s41591-018-0052-4","article-title":"An inhibitor of oxidative phosphorylation exploits cancer vulnerability","volume":"24","author":"Molina","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2026.117888_b0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.mito.2024.101952","article-title":"SDHAF2 facilitates mitochondrial respiration through stabilizing succinate dehydrogenase and cytochrome c oxidase assemblies","volume":"79","author":"Chen","year":"2024","journal-title":"Mitochondrion"},{"issue":"7824","key":"10.1016\/j.bcp.2026.117888_b0400","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41586-020-2475-6","article-title":"Mitochondrial ubiquinol oxidation is necessary for tumour growth","volume":"585","author":"Mart\u00ednez-Reyes","year":"2020","journal-title":"Nature"},{"issue":"5724","key":"10.1016\/j.bcp.2026.117888_b0405","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/280696a0","article-title":"Membrane crystals of ubiquinone:cytochrome c reductase from Neurospora mitochondria","volume":"280","author":"Wingfield","year":"1979","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.bcp.2026.117888_b0410","doi-asserted-by":"crossref","first-page":"136","DOI":"10.5114\/pm.2014.42717","article-title":"Mitochondrial dysfunction in cancer","volume":"13","author":"Ksi\u0119\u017cakowska-\u0141akoma","year":"2014","journal-title":"Przeglad Menopauzalny = Menopause Review"},{"issue":"5","key":"10.1016\/j.bcp.2026.117888_b0415","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s11910-023-01265-3","article-title":"Therapies for IDH-mutant gliomas","volume":"23","author":"Alshiekh Nasany","year":"2023","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"6132","key":"10.1016\/j.bcp.2026.117888_b0420","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1126\/science.1236062","article-title":"An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells","volume":"340","author":"Rohle","year":"2013","journal-title":"Science (New York, N.Y.)"},{"issue":"2","key":"10.1016\/j.bcp.2026.117888_b0425","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10020049","article-title":"Beyond brooding on oncometabolic havoc in IDH-mutant gliomas and AML: current and future therapeutic strategies","volume":"10","author":"Madala","year":"2018","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.bcp.2026.117888_b0430","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1021\/acsmedchemlett.7b00421","article-title":"Discovery of AG-120 (ivosidenib): a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers","volume":"9","author":"Popovici-Muller","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"issue":"25","key":"10.1016\/j.bcp.2026.117888_b0435","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.bcp.2026.117888_b0440","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.bcp.2026.117888_b0445","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1021\/acs.jmedchem.9b01423","article-title":"Structure-based design and identification of FT-2102 (olutasidenib), a potent mutant-selective IDH1 inhibitor","volume":"63","author":"Caravella","year":"2020","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.bcp.2026.117888_b0450","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s40263-019-00684-6","article-title":"Novel IDH1-targeted glioma therapies","volume":"33","author":"Karpel-Massler","year":"2019","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.bcp.2026.117888_b0455","doi-asserted-by":"crossref","first-page":"12758","DOI":"10.1038\/s41598-017-12630-x","article-title":"Assessing inhibitors of mutant isocitrate dehydrogenase using a suite of pre-clinical discovery assays","volume":"7","author":"Urban","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.bcp.2026.117888_b0460","doi-asserted-by":"crossref","first-page":"16458","DOI":"10.1038\/s41598-017-16427-w","article-title":"Allosteric inhibitor remotely modulates the conformation of the orthestric pockets in mutant IDH2\/R140Q","volume":"7","author":"Chen","year":"2017","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.bcp.2026.117888_b0465","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","article-title":"Acute myeloid leukemia: current progress and future directions","volume":"11","author":"Kantarjian","year":"2021","journal-title":"Blood Cancer J."},{"issue":"6","key":"10.1016\/j.bcp.2026.117888_b0470","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bcp.2026.117888_b0475","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1021\/acsmedchemlett.9b00509","article-title":"Vorasidenib (AG-881): a first-in-class, brain-penetrant dual inhibitor of mutant IDH1 and 2 for treatment of glioma","volume":"11","author":"Konteatis","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"issue":"4","key":"10.1016\/j.bcp.2026.117888_b0480","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1016\/j.bbrc.2018.08.068","article-title":"Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2","volume":"503","author":"Ma","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"16","key":"10.1016\/j.bcp.2026.117888_b0485","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1158\/1078-0432.CCR-21-0611","article-title":"Vorasidenib, a dual inhibitor of mutant IDH1\/2, in recurrent or progressive glioma; results of a first-in-human phase I trial","volume":"27","author":"Mellinghoff","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.bcp.2026.117888_b0490","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2013-10-533604","article-title":"IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition","volume":"125","author":"Kernytsky","year":"2015","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bcp.2026.117888_b0495","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1021\/acsmedchemlett.7b00342","article-title":"Discovery and evaluation of clinical candidate IDH305, a brain penetrant mutant IDH1 inhibitor","volume":"8","author":"Cho","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"issue":"2","key":"10.1016\/j.bcp.2026.117888_b0500","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1021\/acsmedchemlett.6b00334","article-title":"Optimization of 3-pyrimidin-4-yl-oxazolidin-2-ones as allosteric and mutant specific inhibitors of IDH1","volume":"8","author":"Levell","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bcp.2026.117888_b0505","doi-asserted-by":"crossref","unstructured":"F. Neumaier, B.D. Zlatopolskiy, B. Neumaier, Mutated isocitrate dehydrogenase (mIDH) as target for PET imaging in gliomas. Molecules (Basel, Switzerland) 2023, 28(7). Doi: 10.3390\/molecules28072890.","DOI":"10.3390\/molecules28072890"},{"issue":"11","key":"10.1016\/j.bcp.2026.117888_b0510","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/nchembio.1930","article-title":"New IDH1 mutant inhibitors for treatment of acute myeloid leukemia","volume":"11","author":"Okoye-Okafor","year":"2015","journal-title":"Nat. Chem. Biol."},{"issue":"2","key":"10.1016\/j.bcp.2026.117888_b0515","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1074\/jbc.M114.608497","article-title":"Selective inhibition of mutant isocitrate dehydrogenase 1 (IDH1) via disruption of a metal binding network by an allosteric small molecule","volume":"290","author":"Deng","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.bcp.2026.117888_b0520","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1038\/leu.2017.46","article-title":"Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo","volume":"31","author":"Chaturvedi","year":"2017","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.bcp.2026.117888_b0525","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s11899-021-00619-3","article-title":"IDH inhibitors in AML-promise and pitfalls","volume":"16","author":"McMurry","year":"2021","journal-title":"Curr. Hematol. Malig. Rep."},{"issue":"23","key":"10.1016\/j.bcp.2026.117888_b0530","doi-asserted-by":"crossref","first-page":"5625","DOI":"10.1016\/j.bmcl.2015.10.034","article-title":"Discovery of \u03b1-mangostin as a novel competitive inhibitor against mutant isocitrate dehydrogenase-1","volume":"25","author":"Kim","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"1","key":"10.1016\/j.bcp.2026.117888_b0535","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/s41591-023-02473-7","article-title":"Author correction: Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial","volume":"30","author":"Mellinghoff","year":"2024","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.bcp.2026.117888_b0540","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s43018-021-00201-z","article-title":"Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas","volume":"2","author":"Friedrich","year":"2021","journal-title":"Nature Cancer"},{"issue":"7","key":"10.1016\/j.bcp.2026.117888_b0545","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/s43018-021-00231-7","article-title":"2-HG modulates glioma macrophages via Trp metabolism","volume":"2","author":"Halaby","year":"2021","journal-title":"Nature Cancer"},{"issue":"3","key":"10.1016\/j.bcp.2026.117888_b0550","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41591-022-02141-2","article-title":"Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial","volume":"29","author":"Mellinghoff","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2026.117888_b0555","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116717","article-title":"The function and mechanism of clinical trial agent CPI-613 in multiple myeloma","volume":"232","author":"Wang","year":"2025","journal-title":"Biochem. Pharmacol."},{"issue":"20","key":"10.1016\/j.bcp.2026.117888_b0560","doi-asserted-by":"crossref","first-page":"8631","DOI":"10.1021\/acs.jmedchem.7b01231","article-title":"Methyl 3-(3-(4-(2,4,4-trimethylpentan-2-yl)phenoxy)-propanamido)benzoate as a novel and dual malate dehydrogenase (MDH) 1\/2 inhibitor targeting cancer metabolism","volume":"60","author":"Naik","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.117888_b0565","doi-asserted-by":"crossref","unstructured":"H.J. Kim, M.K. Park, H.J. Byun, M. Kim, B. Kim, L. Yu, T.M. Nguyen, T.H. Nguyen, P.A. Do, E.J. Kim, et al., LW1497, an Inhibitor of malate dehydrogenase, suppresses TGF-\u03b21-induced epithelial-mesenchymal transition in lung cancer cells by downregulating slug. Antioxidants (Basel, Switzerland) 2021, 10(11). Doi: 10.3390\/antiox10111674.","DOI":"10.3390\/antiox10111674"},{"issue":"9","key":"10.1016\/j.bcp.2026.117888_b0570","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0162568","article-title":"A novel malate dehydrogenase 2 inhibitor suppresses hypoxia-inducible factor-1 by regulating mitochondrial respiration","volume":"11","author":"Ban","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2026.117888_b0575","doi-asserted-by":"crossref","unstructured":"S. Godesi, J.R. Han, J.K. Kim, D.I. Kwak, J. Lee, H. Nada, M. Kim, H.A. Yang, J.Y. Im, H.S. Ban, et al., Design, synthesis and biological evaluation of novel MDH inhibitors targeting tumor microenvironment. Pharmaceuticals (Basel, Switzerland) 2023, 16(5). Doi: 10.3390\/ph16050683.","DOI":"10.3390\/ph16050683"},{"issue":"5","key":"10.1016\/j.bcp.2026.117888_b0580","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1158\/2159-8290.CD-16-1034","article-title":"AG-221, a first-in-class therapy targeting acute myeloid leukemia harboring oncogenic IDH2 mutations","volume":"7","author":"Yen","year":"2017","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.bcp.2026.117888_b0585","doi-asserted-by":"crossref","first-page":"7877","DOI":"10.1038\/s41467-024-51692-0","article-title":"Biostructural, biochemical and biophysical studies of mutant IDH1","volume":"15","author":"McCoy","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.117888_b0590","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.982424","article-title":"Recent advances of IDH1 mutant inhibitor in cancer therapy","volume":"13","author":"Tian","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"7","key":"10.1016\/j.bcp.2026.117888_b0595","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s42452-025-07293-7","article-title":"Scaffold modification and synthesis routes for targeting mutant IDH 1: a review","volume":"7","author":"Pai","year":"2025","journal-title":"Discover Appl. Sci."},{"key":"10.1016\/j.bcp.2026.117888_b0600","series-title":"ML309: a Potent inhibitor of R132H mutant IDH1 capable of reducing 2-hydroxyglutarate production in U87 MG glioblastoma cells","author":"Davis","year":"2010"},{"issue":"10","key":"10.1016\/j.bcp.2026.117888_b0605","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1021\/ml300225h","article-title":"Discovery of the first potent inhibitors of mutant IDH1 that lower tumor 2-HG in vivo","volume":"3","author":"Popovici-Muller","year":"2012","journal-title":"ACS Med. Chem. Lett."},{"issue":"Pt 3","key":"10.1016\/j.bcp.2026.117888_b0610","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1042\/bj3480607","article-title":"Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain","volume":"348 Pt 3","author":"Owen","year":"2000","journal-title":"Biochem. J."},{"issue":"2","key":"10.1016\/j.bcp.2026.117888_b0615","article-title":"Repression of LKB1 by miR-17\u223c92 sensitizes MYC-dependent lymphoma to biguanide treatment","volume":"1","author":"Izreig","year":"2020","journal-title":"Cell Rep. Med."},{"issue":"5","key":"10.1016\/j.bcp.2026.117888_b0620","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s10637-022-01277-9","article-title":"First-in-human study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors","volume":"40","author":"Janku","year":"2022","journal-title":"Invest. New Drugs"},{"issue":"5","key":"10.1016\/j.bcp.2026.117888_b0625","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/cam4.112","article-title":"BAY 87-2243, a highly potent and selective inhibitor of hypoxia-induced gene activation has antitumor activities by inhibition of mitochondrial complex I","volume":"2","author":"Ellinghaus","year":"2013","journal-title":"Cancer Med."},{"key":"10.1016\/j.bcp.2026.117888_b0630","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40170-015-0138-0","article-title":"Targeting mitochondrial complex I using BAY 87-2243 reduces melanoma tumor growth","volume":"3","author":"Sch\u00f6ckel","year":"2015","journal-title":"Cancer Metab."},{"issue":"3","key":"10.1016\/j.bcp.2026.117888_b0635","doi-asserted-by":"crossref","first-page":"e2716","DOI":"10.1038\/cddis.2017.133","article-title":"Mitochondrial complex I inhibition triggers a mitophagy-dependent ROS increase leading to necroptosis and ferroptosis in melanoma cells","volume":"8","author":"Basit","year":"2017","journal-title":"Cell Death Dis."},{"issue":"6","key":"10.1016\/j.bcp.2026.117888_b0640","first-page":"4547","article-title":"BAY 87-2243 sensitizes hepatocellular carcinoma Hep3B cells to histone deacetylase inhibitors treatment via GSK-3\u03b2 activation","volume":"17","author":"Li","year":"2019","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.bcp.2026.117888_b0645","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115576","article-title":"Synthesis and biological evaluation of novel pyrazole amides as potent mitochondrial complex I inhibitors","volume":"258","author":"Zhou","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bcp.2026.117888_b0650","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202101862R","article-title":"Exploiting the tumor immune microenvironment and immunometabolism using mitochondria-targeted drugs: challenges and opportunities in racial disparity and cancer outcome research","volume":"36","author":"Kalyanaraman","year":"2022","journal-title":"FASEB J."},{"key":"10.1016\/j.bcp.2026.117888_b0655","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctarc.2020.100210","article-title":"Mitochondria-targeted magnolol inhibits OXPHOS, proliferation, and tumor growth via modulation of energetics and autophagy in melanoma cells","volume":"25","author":"Cheng","year":"2020","journal-title":"Cancer Treatment Res. Commun."},{"issue":"1","key":"10.1016\/j.bcp.2026.117888_b0660","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1021\/acs.jmedchem.1c01509","article-title":"Discovery and lead optimization of benzene-1,4-disulfonamides as oxidative phosphorylation inhibitors","volume":"65","author":"Xue","year":"2022","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bcp.2026.117888_b0665","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1021\/acs.jmedchem.1c01934","article-title":"Multiparameter optimization of oxidative phosphorylation inhibitors for the treatment of pancreatic cancer","volume":"65","author":"Xue","year":"2022","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.bcp.2026.117888_b0670","doi-asserted-by":"crossref","first-page":"5259","DOI":"10.7150\/thno.42705","article-title":"Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition","volume":"10","author":"Raninga","year":"2020","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.bcp.2026.117888_b0675","first-page":"39","article-title":"Mechanism of action of the atypical retinoid ST1926 in colorectal cancer: DNA damage and DNA polymerase \u03b1","volume":"8","author":"Abdel-Samad","year":"2018","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.bcp.2026.117888_b0680","article-title":"ST1926 inhibits glioma progression through regulating mitochondrial complex II","volume":"128","author":"De","year":"2020","journal-title":"Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie"},{"issue":"34","key":"10.1016\/j.bcp.2026.117888_b0685","doi-asserted-by":"crossref","first-page":"26558","DOI":"10.1074\/jbc.M109.063255","article-title":"Phenethyl isothiocyanate inhibits oxidative phosphorylation to trigger reactive oxygen species-mediated death of human prostate cancer cells","volume":"285","author":"Xiao","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2026.117888_b0690","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1038\/ncomms4295","article-title":"Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments","volume":"5","author":"Zhang","year":"2014","journal-title":"Nat. Commun."},{"issue":"51","key":"10.1016\/j.bcp.2026.117888_b0695","doi-asserted-by":"crossref","first-page":"5372","DOI":"10.18632\/oncotarget.27166","article-title":"A novel tumor spheroid model identifies selective enhancement of radiation by an inhibitor of oxidative phosphorylation","volume":"10","author":"Karlsson","year":"2019","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.bcp.2026.117888_b0700","first-page":"689","article-title":"Anti-cancer analogues ME-143 and ME-344 exert toxicity by directly inhibiting mitochondrial NADH: ubiquinone oxidoreductase (complex I)","volume":"5","author":"Lim","year":"2015","journal-title":"Am. J. Cancer Res."},{"issue":"2","key":"10.1016\/j.bcp.2026.117888_b0705","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1124\/jpet.115.229344","article-title":"Redox signaling and bioenergetics influence lung cancer cell line sensitivity to the isoflavone ME-344","volume":"358","author":"Manevich","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"16","key":"10.1016\/j.bcp.2026.117888_b0710","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1158\/0008-5472.CAN-18-3503","article-title":"Isoflavone ME-344 disrupts redox homeostasis and mitochondrial function by targeting heme oxygenase 1","volume":"79","author":"Zhang","year":"2019","journal-title":"Cancer Res."},{"issue":"31","key":"10.1016\/j.bcp.2026.117888_b0715","doi-asserted-by":"crossref","first-page":"49777","DOI":"10.18632\/oncotarget.10446","article-title":"A novel isoflavone, ME-344, targets the cytoskeleton in acute myeloid leukemia","volume":"7","author":"Jeyaraju","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2026.117888_b0720","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114253","article-title":"Targeting mitochondrial respiration for the treatment of acute myeloid leukemia","volume":"182","author":"Carter","year":"2020","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117888_b0725","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1038\/s41467-019-10042-1","article-title":"Targeting lonidamine to mitochondria mitigates lung tumorigenesis and brain metastasis","volume":"10","author":"Cheng","year":"2019","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.bcp.2026.117888_b0730","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.plipres.2013.06.002","article-title":"Mitochondrial membrane lipid remodeling in pathophysiology: a new target for diet and therapeutic interventions","volume":"52","author":"Monteiro","year":"2013","journal-title":"Prog. Lipid Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.117888_b0735","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20181661","article-title":"Minerval (2-hydroxyoleic acid) causes cancer cell selective toxicity by uncoupling oxidative phosphorylation and compromising bioenergetic compensation capacity","volume":"39","author":"Massalha","year":"2019","journal-title":"Biosci. Rep."},{"issue":"21\u201322","key":"10.1016\/j.bcp.2026.117888_b0740","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.lfs.2010.04.003","article-title":"Disturbance of mitochondrial energy homeostasis caused by the metabolites accumulating in LCHAD and MTP deficiencies in rat brain","volume":"86","author":"Tonin","year":"2010","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.bcp.2026.117888_b0745","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1085\/jgp.106.1.67","article-title":"The relationship between membrane fluidity and permeabilities to water, solutes, ammonia, and protons","volume":"106","author":"Lande","year":"1995","journal-title":"J. Gen. Physiol."},{"issue":"5","key":"10.1016\/j.bcp.2026.117888_b0750","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.bbamem.2013.01.013","article-title":"The role of membrane fatty acid remodeling in the antitumor mechanism of action of 2-hydroxyoleic acid","volume":"1828","author":"Martin","year":"2013","journal-title":"BBA"},{"issue":"7748","key":"10.1016\/j.bcp.2026.117888_b0755","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41586-019-0993-x","article-title":"Gboxin is an oxidative phosphorylation inhibitor that targets glioblastoma","volume":"567","author":"Shi","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2026.117888_b0760","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115531","article-title":"OXPHOS inhibitors, metabolism and targeted therapies in cancer","volume":"211","author":"Cadassou","year":"2023","journal-title":"Biochem. Pharmacol."},{"issue":"5","key":"10.1016\/j.bcp.2026.117888_b0765","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200924","article-title":"Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia","volume":"218","author":"Stuani","year":"2021","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.117888_b0770","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1146\/annurev-cancerbio-042016-073434","article-title":"Synthetic lethality in cancer therapeutics","volume":"1","author":"Beijersbergen","year":"2017","journal-title":"Ann. Rev. Cancer Biol."},{"issue":"9","key":"10.1016\/j.bcp.2026.117888_b0775","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nmeth921","article-title":"shRNA libraries and their use in cancer genetics","volume":"3","author":"Bernards","year":"2006","journal-title":"Nat. Methods"},{"issue":"6166","key":"10.1016\/j.bcp.2026.117888_b0780","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.1247005","article-title":"Genome-scale CRISPR-Cas9 knockout screening in human cells","volume":"343","author":"Shalem","year":"2014","journal-title":"Science (New York, N.Y.)"},{"issue":"5","key":"10.1016\/j.bcp.2026.117888_b0785","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.celrep.2014.07.053","article-title":"Hexokinase 2-mediated Warburg effect is required for PTEN- and p53-deficiency-driven prostate cancer growth","volume":"8","author":"Wang","year":"2014","journal-title":"Cell Rep."},{"issue":"7501","key":"10.1016\/j.bcp.2026.117888_b0790","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nature13166","article-title":"High-throughput screening of a CRISPR\/Cas9 library for functional genomics in human cells","volume":"509","author":"Zhou","year":"2014","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.bcp.2026.117888_b0795","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/nprot.2014.103","article-title":"Functional genomics platform for pooled screening and generation of mammalian genetic interaction maps","volume":"9","author":"Kampmann","year":"2014","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.bcp.2026.117888_b0800","doi-asserted-by":"crossref","first-page":"8083","DOI":"10.1038\/ncomms9083","article-title":"Rapid and efficient one-step generation of paired gRNA CRISPR-Cas9 libraries","volume":"6","author":"Vidigal","year":"2015","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.bcp.2026.117888_b0805","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1073\/pnas.1517883113","article-title":"Multiplexed barcoded CRISPR-Cas9 screening enabled by CombiGEM","volume":"113","author":"Wong","year":"2016","journal-title":"PNAS"},{"issue":"1","key":"10.1016\/j.bcp.2026.117888_b0810","doi-asserted-by":"crossref","first-page":"e248","DOI":"10.1038\/cddis.2011.123","article-title":"Cancer metabolism: current perspectives and future directions","volume":"3","author":"Mu\u00f1oz-Pinedo","year":"2012","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.bcp.2026.117888_b0815","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41571-024-00966-z","article-title":"Synthetic lethal strategies for the development of cancer therapeutics","volume":"22","author":"Ngoi","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117888_b0820","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s13046-021-02054-x","article-title":"Synthetic lethality and synergetic effect: the effective strategies for therapy of IDH-mutated cancers","volume":"40","author":"Yao","year":"2021","journal-title":"J. Exp. Clin. Cancer Res.: CR"},{"issue":"3","key":"10.1016\/j.bcp.2026.117888_b0825","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1021\/acs.jmedchem.8b00961","article-title":"Overview of the development of glutaminase inhibitors: achievements and future directions","volume":"62","author":"Xu","year":"2019","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.bcp.2026.117888_b0830","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.cmet.2017.10.001","article-title":"InVivo imaging of glutamine metabolism to the oncometabolite 2-hydroxyglutarate in IDH1\/2 mutant tumors","volume":"26","author":"Salamanca-Cardona","year":"2017","journal-title":"Cell Metab."},{"issue":"4","key":"10.1016\/j.bcp.2026.117888_b0835","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.exphem.2013.12.001","article-title":"Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations","volume":"42","author":"Emadi","year":"2014","journal-title":"Exp. Hematol."},{"issue":"3","key":"10.1016\/j.bcp.2026.117888_b0840","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/s41419-019-1407-6","article-title":"BCL-2 family isoforms in apoptosis and cancer","volume":"10","author":"Warren","year":"2019","journal-title":"Cell Death Dis."},{"issue":"4706","key":"10.1016\/j.bcp.2026.117888_b0845","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1126\/science.3874430","article-title":"Involvement of the bcl-2 gene in human follicular lymphoma","volume":"228","author":"Tsujimoto","year":"1985","journal-title":"Science (New York, N.Y.)"},{"issue":"2","key":"10.1016\/j.bcp.2026.117888_b0850","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nm.3788","article-title":"Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia","volume":"21","author":"Chan","year":"2015","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.bcp.2026.117888_b0855","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.bcp.2026.117888_b0860","doi-asserted-by":"crossref","first-page":"726","DOI":"10.4161\/cc.28104","article-title":"The histone methyltransferase Dot1\/DOT1L as a critical regulator of the cell cycle","volume":"13","author":"Kim","year":"2014","journal-title":"Cell Cycle (Georgetown, Tex)"},{"issue":"12","key":"10.1016\/j.bcp.2026.117888_b0865","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1038\/leu.2014.235","article-title":"Primary acute myeloid leukemia cells with IDH1 or IDH2 mutations respond to a DOT1L inhibitor in vitro","volume":"28","author":"Sarkaria","year":"2014","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.bcp.2026.117888_b0870","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nrm3757","article-title":"Making new contacts: the mTOR network in metabolism and signalling crosstalk","volume":"15","author":"Shimobayashi","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"2","key":"10.1016\/j.bcp.2026.117888_b0875","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.cell.2017.03.035","article-title":"mTOR signaling in growth, metabolism, and disease","volume":"169","author":"Saxton","year":"2017","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.bcp.2026.117888_b0880","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13046-017-0544-y","article-title":"Rapamycin (mTORC1 inhibitor) reduces the production of lactate and 2-hydroxyglutarate oncometabolites in IDH1 mutant fibrosarcoma cells","volume":"36","author":"Hujber","year":"2017","journal-title":"J. Exp. Clin. Cancer Res.: CR"},{"issue":"49","key":"10.1016\/j.bcp.2026.117888_b0885","doi-asserted-by":"crossref","first-page":"5636","DOI":"10.1038\/sj.onc.1203912","article-title":"Role of Src expression and activation in human cancer","volume":"19","author":"Irby","year":"2000","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.bcp.2026.117888_b0890","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1158\/2159-8290.CD-15-1442","article-title":"Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC dependence in intrahepatic cholangiocarcinoma","volume":"6","author":"Saha","year":"2016","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.bcp.2026.117888_b0895","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1158\/1535-7163.MCT-19-0103","article-title":"Blockade of glutathione metabolism in IDH1-mutated glioma","volume":"19","author":"Tang","year":"2020","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.bcp.2026.117888_b0900","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1101\/gad.13.1.76","article-title":"Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain","volume":"13","author":"Itoh","year":"1999","journal-title":"Genes Dev."},{"issue":"11","key":"10.1016\/j.bcp.2026.117888_b0905","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.molmed.2004.09.003","article-title":"Nrf2-Keap1 defines a physiologically important stress response mechanism","volume":"10","author":"Motohashi","year":"2004","journal-title":"Trends Mol. Med."},{"issue":"15","key":"10.1016\/j.bcp.2026.117888_b0910","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1089\/ars.2017.7121","article-title":"Mitochondrial glutathione: regulation and functions","volume":"27","author":"Calabrese","year":"2017","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.bcp.2026.117888_b0915","doi-asserted-by":"crossref","first-page":"15580","DOI":"10.1038\/ncomms15580","article-title":"Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data","volume":"8","author":"Sinha","year":"2017","journal-title":"Nat. Commun."},{"issue":"375","key":"10.1016\/j.bcp.2026.117888_b0920","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal2463","article-title":"2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity","volume":"9","author":"Sulkowski","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"17","key":"10.1016\/j.bcp.2026.117888_b0925","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaz3221","article-title":"Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas","volume":"6","author":"Wang","year":"2020","journal-title":"Sci. Adv."},{"issue":"7","key":"10.1016\/j.bcp.2026.117888_b0930","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1158\/0008-5472.CAN-16-2773","article-title":"Chemosensitivity of IDH1-mutated gliomas due to an impairment in PARP1-mediated DNA repair","volume":"77","author":"Lu","year":"2017","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.bcp.2026.117888_b0935","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/ncb3233","article-title":"Pyruvate carboxylation enables growth of SDH-deficient cells by supporting aspartate biosynthesis","volume":"17","author":"Cardaci","year":"2015","journal-title":"Nat. Cell Biol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117888_b0940","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41392-020-00358-6","article-title":"Development of synthetic lethality in cancer: molecular and cellular classification","volume":"5","author":"Li","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bcp.2026.117888_b0945","doi-asserted-by":"crossref","first-page":"8784","DOI":"10.1038\/ncomms9784","article-title":"Loss of succinate dehydrogenase activity results in dependency on pyruvate carboxylation for cellular anabolism","volume":"6","author":"Lussey-Lepoutre","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.117888_b0950","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.semcdb.2019.05.002","article-title":"Fumarate hydratase in cancer: a multifaceted tumour suppressor","volume":"98","author":"Schmidt","year":"2020","journal-title":"Semin. Cell Dev. Biol."},{"issue":"2","key":"10.1016\/j.bcp.2026.117888_b0955","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ccr.2012.12.007","article-title":"Englerin a stimulates PKC\u03b8 to inhibit insulin signaling and to simultaneously activate HSF1: pharmacologically induced synthetic lethality","volume":"23","author":"Sourbier","year":"2013","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.bcp.2026.117888_b0960","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.cmet.2023.12.003","article-title":"Metabolic switch regulates lineage plasticity and induces synthetic lethality in triple-negative breast cancer","volume":"36","author":"Zhang","year":"2024","journal-title":"Cell Metab."},{"issue":"1","key":"10.1016\/j.bcp.2026.117888_b0965","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1038\/s41467-025-57225-7","article-title":"A metabolic synthetic lethality of phosphoinositide 3-kinase-driven cancer","volume":"16","author":"Andrieu","year":"2025","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bcp.2026.117888_b0970","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13046-022-02240-5","article-title":"Metabolic synthetic lethality by targeting NOP56 and mTOR in KRAS-mutant lung cancer","volume":"41","author":"Yang","year":"2022","journal-title":"J. Exp. Clin. Cancer Res.: CR"},{"issue":"1","key":"10.1016\/j.bcp.2026.117888_b0975","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s12943-024-02119-3","article-title":"Altered metabolism in cancer: insights into energy pathways and therapeutic targets","volume":"23","author":"Tufail","year":"2024","journal-title":"Mol. Cancer"},{"issue":"274","key":"10.1016\/j.bcp.2026.117888_b0980","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa1009","article-title":"Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo","volume":"7","author":"Venneti","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bcp.2026.117888_b0985","article-title":"Metabolomic biomarkers in liquid biopsy: accurate cancer diagnosis and prognosis monitoring","volume":"14","author":"Wang","year":"2024","journal-title":"Front. Oncol."},{"issue":"9","key":"10.1016\/j.bcp.2026.117888_b0990","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007146","article-title":"Inhibition of TCA cycle improves the anti-PD-1 immunotherapy efficacy in melanoma cells via ATF3-mediated PD-L1 expression and glycolysis","volume":"11","author":"Liu","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"8","key":"10.1016\/j.bcp.2026.117888_b0995","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.cmet.2022.06.008","article-title":"Tumor cells dictate anti-tumor immune responses by altering pyruvate utilization and succinate signaling in CD8(+) Tcells","volume":"34","author":"Elia","year":"2022","journal-title":"Cell Metab."},{"issue":"1","key":"10.1016\/j.bcp.2026.117888_b1000","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-021-01316-8","article-title":"The cancer metabolic reprogramming and immune response","volume":"20","author":"Xia","year":"2021","journal-title":"Mol. Cancer"},{"issue":"2","key":"10.1016\/j.bcp.2026.117888_bib1001","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/neuonc\/noac155","article-title":"The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas","volume":"25","author":"Natsume","year":"2023","journal-title":"Neuro Oncol"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226002212?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226002212?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T22:17:44Z","timestamp":1778710664000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226002212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":201,"alternative-id":["S0006295226002212"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.117888","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic targeting of tricarboxylic acid cycle and oxidative phosphorylation: a critical analysis of metabolic interventions in cancer treatment","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.117888","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117888"}}